Versoteq

Blog


Press release: Versoteq Delivers Medical 3D Printing Application

Espoo, Finland, 12 August 2015 - Versoteq, in partnership with Peacocks Medical Group and the University of Newcastle, has been awarded significant funding for developing tailored CAD tools for the design of innovative foot orthoses using 3D-printing technologies.

The project for optimised foot orthoses was commissioned and funded by the National Heath Service England (NHS England) through the Small Business Research Initiative for Healthcare (SBRI Healthcare) competition. A total of £1.25 million is funded to 14 small businesses working in different healthcare areas. The aim of the competition is to accelerate the development of innovative products and technologies that address unmet health needs.

In the project, Versoteq delivers tailored computer aided software for the fast customisation of 3D printed foot orthoses. The delivered software solution is an evolved and specialised version of Versoteq's core 3D technology. The outcome of the project merits Versoteq with its first major medical application.

3D printing has been adopted in manufacturing customised medical devices because of the unprecedented freedom of design it offers to the designers. It also improves efficiency in mass tailoring in such a way that multiple individualised items can be produced simultaneously, as in designing foot orthoses. Foot orthoses are used for treating and preventing a number of musculoskeletal anomalies and disabilities, for example heel pain, plantar fasciitis, metatarsalgia or diabetes, improving the quality of many people’s daily lives.

For more information about Peacocks and the application please contact Dr. Jari Pallari jari.pallari(at)peacocks.net. For more information about Versoteq's software solutions please contact Mr. Timo Yletyinen, Tel. +358443006654 or timo.yletyinen(at)versoteq.com.

This work was commissioned and funded by NHS England. The views expressed in the publication are those of the author(s) and not necessarily that of the funding partners.

Share